Walter M Gregory
Overview
Explore the profile of Walter M Gregory including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
3350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Tute R, Pawlyn C, Cairns D, Davies F, Menzies T, Rawstron A, et al.
J Clin Oncol
. 2022 Apr;
40(25):2889-2900.
PMID: 35377708
Purpose: Minimal residual disease (MRD) can predict outcomes in patients with multiple myeloma, but limited data are available on the prognostic impact of MRD when assessed at serial time points...
2.
Jackson G, Pawlyn C, Cairns D, De Tute R, Hockaday A, Collett C, et al.
PLoS Med
. 2021 Jan;
18(1):e1003454.
PMID: 33428632
Background: Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious in the treatment of myeloma and carries less risk of peripheral neuropathy than first-generation proteasome inhibitors, making it more...
3.
Howard D, Hockaday A, Brown J, Gregory W, Todd S, Munir T, et al.
Trials
. 2021 Jan;
22(1):38.
PMID: 33419469
Background: The FLAIR trial in chronic lymphocytic leukaemia has a randomised, controlled, open-label, confirmatory, platform design. FLAIR was successfully amended to include an emerging promising experimental therapy to expedite its...
4.
Croft J, Ellis S, Sherborne A, Sharp K, Price A, Jenner M, et al.
Leukemia
. 2020 Dec;
35(7):2043-2053.
PMID: 33262523
Structural chromosomal changes including copy number aberrations (CNAs) are a major feature of multiple myeloma (MM), however their evolution in context of modern biological therapy is not well characterized. To...
5.
Jackson G, Pawlyn C, Cairns D, Striha A, Collett C, Waterhouse A, et al.
Br J Haematol
. 2020 Jul;
192(5):853-868.
PMID: 32656799
Second-generation immunomodulatory agents, such as lenalidomide, have a more favourable side-effect profile than the first-generation thalidomide, but their optimum combination and duration for patients with newly diagnosed transplant-ineligible myeloma (ND-TNE-MM)...
6.
Franks K, McParland L, Webster J, Baldwin D, Sebag-Montefiore D, Evison M, et al.
Eur Respir J
. 2020 Jul;
56(5).
PMID: 32616595
Objectives: Stereotactic ablative radiotherapy (SABR) is a well-established treatment for medically inoperable peripheral stage I nonsmall cell lung cancer (NSCLC). Previous nonrandomised evidence supports SABR as an alternative to surgery,...
7.
Jackson G, Davies F, Pawlyn C, Cairns D, Striha A, Collett C, et al.
Haematologica
. 2020 Jun;
106(7):1957-1967.
PMID: 32499244
The optimal way to use immunomodulatory drugs as components of induction and maintenance therapy for multiple myeloma is unresolved. We addressed this question in a large phase III randomized trial,...
8.
Bradbury C, Craig Z, Cook G, Pawlyn C, Cairns D, Hockaday A, et al.
Blood
. 2020 May;
136(9):1091-1104.
PMID: 32438407
Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs are at high risk of venous thromboembolism (VTE), but data are lacking from large prospective cohorts. We present thrombosis outcome...
9.
Shah V, Sherborne A, Johnson D, Ellis S, Price A, Chowdhury F, et al.
Leukemia
. 2020 Mar;
34(11):3091-3096.
PMID: 32157174
No abstract available.
10.
Jackson G, Davies F, Pawlyn C, Cairns D, Striha A, Collett C, et al.
Lancet Haematol
. 2019 Oct;
6(12):e616-e629.
PMID: 31624047
Background: Multiple myeloma has been shown to have substantial clonal heterogeneity, suggesting that agents with different mechanisms of action might be required to induce deep responses and improve outcomes. Such...